AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02506777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT02506777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT02506777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02506777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin
Study NCT01576081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEPHAISTOS
Description: HEPHAISTOS unloading orthotic
Study NCT00476086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given PO
Study NCT03249454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal tsDCS
Description: During Cathodal tsDCS intervention the negative end of the battery will be connected to the electrode on participant's back and positive end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexagratinib
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Undergo molecular analysis
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib Sulfate
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo magnetic resonance imaging (MRI)
Study NCT03249454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tsDCS
Description: During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.
Study NCT02220335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary arterial denervation
Description: Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
Study NCT02220335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.Patients in the standard treatment group will take one or combination of the following target drugs: endothelin receptor antagonist, 5'-PDE and prostacyclin. On the other hand, patients in the PADN group do not take any of the target drugs mentioned above.
Study NCT02220335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.Patients in the standard treatment group will take one or combination of the following target drugs: endothelin receptor antagonist, 5'-PDE and prostacyclin. On the other hand, patients in the PADN group do not take any of the target drugs mentioned above.
Study NCT04131868 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Typical sleep opportunity
Description: Typical sleep opportunity with consistent sleep timing for 1 week
Study NCT04131868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended sleep opportunity
Description: Extended sleep opportunity by 90 min per night with consistent sleep timing for 1 week
Study NCT00552474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Libra Deep Brain Stimulation System
Description: Active DBS Therapy
Study NCT00552474 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Libra Deep Brain Stimulation System
Description: Implanted system but no stimulation
Study NCT00882388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: aspirin 100 mg qd for 7 days
Study NCT00882388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Description: celecoxib 200 mg bid \* 7 days
Study NCT00882388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin + celecoxib
Description: aspirin 100 mg qd + celecoxib 200 mg bid for 7 days
Study NCT00882388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin + clopidogrel
Description: asprin 100 mg qd + clopidogrel 75 mg qd for 7 days
Study NCT00882388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin + clopidogrel + celecoxib
Description: aspirin 100 mg qd + clopidogrel 75 mg qd + celecoxib 200 mg bid
Study NCT05866328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation and Individual Placement and Support
Description: Cognitive Rehabilitation and Individual Placement and Support
Study NCT02082483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selective Screening
Description: Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
Study NCT03532035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Description: Subjects will receive BCV administered as a continuous IV infusion over 2 hours twice weekly (on Days 1, 4, 8, and 11) for a period of 2 weeks (total of 4 doses).
Study NCT03532035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Subjects randomized to the SoC in each cohort will be managed per local institutional guidelines and investigator judgement. SoC treatment options may include, but are not limited to, taking a watch and-wait approach, with or without decreased immunosuppression (i.e., no active treatment), or treatment with IV CDV, ganciclovir, or ribavirin.
Study NCT02193763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound assisted lumbar puncture
Description: An investigator will perform beside ultrasound on the spinal area using a bedside ultrasound device. Attempts will be made to visualize the spinous processes and vertebral bodies in the general lumbarsacral area, as well as the presence of CSF in the thecal space below the conus medullaris, and identify the optimal location to perform the LP. This will be marked with a skin marker (If no CSF or abnormal anatomy is visualized, the LP will be advised to be postponed or cancelled). The treating physician will then proceed with the LP guided by the skin markings.
Study NCT01810419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vscan Ultrasound (GE Healthcare, USA)
Description: Vscan Ultrasound used to determine spleen size and the other qualities described in the arm description.
Study NCT01810419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Ultrasound
Description: Conventional Ultrasound used to determine spleen size and the other qualities described in the arm description.
Study NCT03154047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEOD001
Description: humanized monoclonal antibody
Study NCT00440167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m², d 1, 8 , 15, q d28
Study NCT00440167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 2 x 1000 mg/m²/ d oral, d 1 - 14 followed by 7 days Pause (Flat Dosing)
Study NCT03079583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention-group
Description: Biofortified Rice is grown by foliar Zn application
Study NCT03079583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control-group
Description: Control Rice with normal zinc levels
Study NCT02357485 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADSC
Description: Single injection of ADSC
Study NCT00440167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib 150 mg/d oral, daily without break
Study NCT00799669 — intervention group
Intervention type: BEHAVIORAL
Intervention: smoking cessation intervention
Description: Standard quit-smoking counseling to help decrease their risk of cancer.
Study NCT03948867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea treatment will be provided to reduce stroke risk. Hydroxyurea treatment will be started at a fixed dose of 20.0 ± 5.0 mg/kg/day, followed by escalation to maximum tolerated dose (MTD).
Study NCT03948867 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Elevated Arm TCD Examination
Description: TCD examination on children with SCA between ages 2 and 16 years of age will be completed to evaluate their risk of stroke.~For children with elevated velocities at initial screening or at 1 Year who receive hydroxyurea therapy, TCD examinations will occur every 6 ± 2 months.
Study NCT03867721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilator
Description: Comparison of two ventilators for mouthpiece ventilation
Study NCT03948867 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Normal Arm TCD Examination
Description: TCD examination on children with SCA between ages 2 and 16 years of age will be completed to evaluate their risk of stroke. TCD examination for all participants will occur at initial screening, at Year 1 (12 ± 3 months), and Year 2 (24 ± 3 months). Children with normal TCD velocities at initial screening will undergo repeat TCD 12 months after enrolment. If the TCD at 12 months has changed to an elevated velocity (conditional or abnormal), the child can begin study treatment (Hydroxyurea).
Study NCT00476086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT00476086 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study NCT01293591 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Subjects will consume a garlic-free diet for 10 days. On day 11, subjects will consume 270 kcal white bread with 15 g margarine.
Study NCT01293591 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Garlic treatment
Description: Subjects will consume a garlic-free diet for 10 days. On day 11, subjects will consume 270 kcal white bread with 15 g margarine and 5 g crushed garlic.
Study NCT04373096 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: current IPAC-UHN PPE
Description: * Fit-tested N95 mask~* Open face shield~* Double extended-cuff
Study NCT04373096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified IPAC-UHN PPE
Description: * Fit-tested N95 mask~* Hood~* Double extended-cuff gloves
Study NCT00952250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Feedback Reports
Description: Sites randomized to this arm will receive specialized feedback summarizing their adherence to the guidelines and suggestions on ways to improve performance.
Study NCT00952250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Feedback Report
Description: Report designed to target areas for local hospital-specific improvement
Study NCT02465060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT02465060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K-beta Inhibitor GSK2636771
Description: Given PO
Study NCT03782896 — intervention group
Intervention type: OTHER
Intervention: acute postoperative pain
Description: All patients assessed postoperative pain score in the recovery room and postoperative 2 month
Study NCT00799669 — intervention group
Intervention type: OTHER
Intervention: counseling intervention
Description: Counseling focusing on decreasing risk of getting cancer by decreasing smoking and alcohol use.
Study NCT02465060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiologic Examination
Description: Undergo radiologic evaluation
Study NCT02465060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo nuclear study
Study NCT01989598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01989598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01989598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Given IV
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study NCT02286050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CF Nursing Program
Study NCT01445691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ALA (Gliolan)
Description: 20 mg/kg administered once 3-5 hours prior to surgery
Study NCT03786172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation Intervention
Description: * A 10 to 15 minute standardised counseling session performed peri-operatively by an ENT resident, and based on the 5 As motivational interviewing model (Ask, Advise, Assess, Assist, Arrange)~* A motivational gadget distributed to the patients~* Nicotine replacement therapy (NRT), consisting of nicotine transdermal patches for 8 weeks, offered to the patients
Study NCT03786172 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: A 10-second brief advice to quit smoking, performed peri-operatively by an ENT resident
Study NCT04267276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: BI 1265162 - intravenous
Description: Intravenous solution
Study NCT04267276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: BI 1265162 - oral
Description: Oral solution
Study NCT01989598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprosertib
Description: Given PO
Study NCT03605342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, which is standard practice.
Study NCT00799669 — intervention group
Intervention type: OTHER
Intervention: preventive intervention
Study NCT03605342 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Description: CPT-C is a manualized, 12-session 1:1 cognitive therapy that has been designed for patients with PTSD. In this study the sessions will be conducted weekly. CPT-C uses Socratic questioning targeting distorted cognitions such as self-blame, hindsight bias, and other guilt cognitions. CPT-C is focused on the cognitive components of the therapy without exposure.
Study NCT03605342 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Drug Counseling (IDC)
Description: IDC will serve as the control group. The current standard of treatment for Veterans entering buprenorphine maintenance is to do drug counseling. Standard counseling is the primary means to achieve goals. IDC uses a semi-structured, time-limited addictions-counseling model in a 1:1 setting. The IDC manual provides an organized, concise version of what is currently practiced by most addiction counselors.
Study NCT00799669 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Study NCT04568512 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Brushed biliary samples from a known case of benign biliary stricture were sent for DNA Methylation Biomarker test and cell cytology
Study NCT03106415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study NCT03106415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03106415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04246476 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mentally singing
Description: All participants (people with PD and age-matched controls) sing their song in their head and match their footfalls or finger tapping to the beat.
Study NCT04246476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentally singing
Description: All participants (people with PD and age-matched controls) sing their song in their head and match their footfalls or finger tapping to the beat.
Study NCT04246476 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Listening to music
Description: All participants (people with PD and age-matched controls) listen to their song and match their footfalls or finger tapping to the beat.
Study NCT04246476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening to music
Description: All participants (people with PD and age-matched controls) listen to their song and match their footfalls or finger tapping to the beat.
Study NCT04568512 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cholangiocarcinoma
Description: Brushed biliary samples from a known case of cholangiocarcinoma were sent for DNA Methylation Biomarker test and cell cytology
Study NCT01763957 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paula Method
Description: All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list.
Study NCT02900092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: Participants received ganaxolone
Study NCT03237013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial Morphing Intervention
Description: Participants assigned to this condition were exposed to facial morphing technology that displays the progression of facial-ageing up to 72years, both with and without damage from UV exposure.
Study NCT03237013 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness Intervention
Description: Participants assigned to this condition engaged in a self-guided mindfulness intervention audio tape. This intervention instructed participants to pay attention to the present moment, with a non-judgemental stance. For example, participants were instructed to notice their breath, thoughts, feelings, physical sensations, and to internally describe them, without passing judgement
Study NCT04548531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Decision Making
Description: The decision aid is a paper information sheet presenting the pros and cons of three screening options (colonoscopy, stool-based tests, and postponing cancer screening until next year).~The decision coaching is a structured interview to help patients clarify their preference for screening test and to support them in implementation (whether scheduling colonoscopy, ordering stool test or seeking additional advice from specialist).
Study NCT02981485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fat Grafting
Description: Treatment of breast cancer related lymphedema by fat grafting
Study NCT00502996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: >=15 mg po/week
Study NCT00502996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1g iv on days 1 and 15
Study NCT03518736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supporting Play Exploration and Developmental Intervention (SPEEDI)
Description: Physical Therapy intervention
Study NCT01347853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: 30 mg intranasal post-surgery for up to 5 days total
Study NCT01347853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal post-surgery for up to 5 days total